Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.23.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Jan. 01, 2022
Assets    
Cash and cash equivalents $ 115 $ 705
Trade and other receivables, net 7,922 4,220
Inventories 366 1,209
Prepaid expenses and other current assets 770 1,423
Current assets from discontinued operations 0 105
Total current assets 9,173 7,557
Property and equipment, net 2,705 2,113
Right of use asset - operating leases 5,290 3,671
Intangible assets-Soin, net 20,033 268
Intangible assets, net 740 268
Note receivable, net 8,974 0
Marketable securities 315 0
Deposits and other assets 266 1,556
Other assets from discontinued operations 0 2
Total assets 46,756 15,165
Liabilities:    
Accounts payable 6,699 5,071
Accrued liabilities - other 4,283 5,232
Accrued liability - California sales taxes 6,264 6,022
Lease obligation short term - operating leases 1,632 1,304
Short term debt 4,553 288
Current portion of note payable 274 261
Related party note 233 1,000
Current liabilities from discontinued operations 0 195
Total current liabilities 23,938 19,373
Lease obligation long term - operating leases 3,816 2,470
Notes payable - long term portion 1,339 1,318
Deferred income taxes, net 195 0
Long-term portion related party note payable 605 0
Other noncurrent liabilities 46 680
Total liabilities 29,939 23,841
Commitments and Contingencies (Note 17)
Stockholders' equity (deficit):    
Common stock, par value $0.001 per share, 200,000,000 shares authorized, 3,150,230 and 2,847,410 shares issued and outstanding at December 31, 2022 and at January 1, 2022, respectively 2 2
Additional paid in capital 45,748 45,743
Accumulated deficit (42,822) (53,804)
Accumulated other comprehensive loss (621) (617)
Total stockholders' equity (deficit) 2,307 (8,676)
Total liabilities and stockholders' equity (deficit) 46,756 15,165
Series S    
Mezzanine equity [Abstract]    
Convertible preferred stock, series S - par value $0.001 per share 200,000 authorized, 100,000 and 0 shares issued and outstanding at December 31, 2022 and January 1, 2022, respectively 14,510
Series A-1    
Stockholders' equity (deficit):    
Convertible preferred stock, series A-1 - par value $0.001 per share 2,000,000 authorized, 222,588 and 238,729 shares issued and outstanding at December 31, 2022 andJanuary 1, 2022, respectively 0 0
Soin Therapeutics LLC [Member]    
Assets    
Intangible assets-Soin, net 19,293 0
Continuing Operations    
Assets    
Inventories 366 1,104
Property and equipment, net $ 2,705 $ 2,111